Sinalização PI3K/Akt/mTOR
Os inibidores da sinalização PI3K/Akt/mTOR são compostos que têm como alvo as vias da fosfoinositídeo 3-quinase (PI3K), da quinase Akt e do alvo da rapamicina em mamíferos (mTOR). Essas vias são reguladores críticos do crescimento celular, sobrevivência, metabolismo e autofagia, tornando-os alvos-chave na pesquisa de câncer e distúrbios metabólicos. A inibição dessas vias pode ajudar a controlar o crescimento e a proliferação tumoral, oferecendo estratégias terapêuticas potenciais para vários tipos de câncer e outras doenças caracterizadas por sinalização celular desregulada. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de alta qualidade de PI3K/Akt/mTOR para apoiar sua pesquisa em oncologia, sinalização celular e doenças metabólicas.
Subcategorias de "Sinalização PI3K/Akt/mTOR"
- AMPK(159 produtos)
- ATM/ATR(71 produtos)
- DNA-PK(51 produtos)
- EGFR(572 produtos)
- MELK(7 produtos)
- PDK(9 produtos)
- PI3K(242 produtos)
- S6 Quinase(9 produtos)
- gsk-3(112 produtos)
- mTOR(144 produtos)
Exibir 2 mais subcategorias
Foram encontrados 1038 produtos de "Sinalização PI3K/Akt/mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-23
CAS:<p>EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.</p>Fórmula:C36H44BrN10O3PCor e Forma:SolidPeso molecular:775.68BPI-15086
CAS:<p>BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.</p>Fórmula:C29H33ClN8O4Cor e Forma:SolidPeso molecular:593.08ES-072
CAS:<p>ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.</p>Fórmula:C25H27F3N8O2Cor e Forma:SolidPeso molecular:528.53NSC381467
CAS:<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C20H16O7Cor e Forma:SolidPeso molecular:368.34EGFR-IN-130
<p>EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.</p>Fórmula:C27H25N3O6SCor e Forma:SolidPeso molecular:519.57BML-265
CAS:<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Fórmula:C18H15N3O2Cor e Forma:SolidPeso molecular:305.3315-Bromo-3-indoxylacetate
CAS:<p>5-Bromo-3-indoxylacetate acts as an inhibitor of GSK-3, with a pIC50 value of 3.39.</p>Fórmula:C10H8BrNO2Cor e Forma:SolidPeso molecular:254.08EGFR-IN-160
CAS:<p>EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).</p>Fórmula:C15H12N2O4Cor e Forma:SolidPeso molecular:284.27PI3K-IN-37
CAS:<p>PI3K-IN-37 inhibits PI3K α/β/δ (IC50: 6/8/4 nM) and mTOR (IC50: 4 nM).</p>Fórmula:C25H26N6O2Cor e Forma:SolidPeso molecular:442.51Sacibertinib
CAS:<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Fórmula:C32H31ClN6O4Cor e Forma:SolidPeso molecular:599.08EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Fórmula:C14H11BrN4O2SCor e Forma:SolidPeso molecular:379.23PI3K-IN-23
<p>PI3K-IN-23 is a (E)-9-oxooctadec-10-en-12-ynoic acid analogue that promotes glucose uptake (EC50: 7.00 μM).</p>Fórmula:C24H33NO4SCor e Forma:SolidPeso molecular:431.59EGFR-IN-132
CAS:<p>EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.</p>Fórmula:C27H31N7O3Cor e Forma:SolidPeso molecular:501.58PI3K-IN-27
CAS:<p>PI3K-IN-27 is a potent PI3K inhibitor, relevant for cancer and immune disease research. See patent WO2021233227A1.</p>Fórmula:C30H26F2N6O2SCor e Forma:SolidPeso molecular:572.63NS-062
CAS:<p>NS-062 is an orally effective, irreversible covalent inhibitor targeting EGFR, demonstrating antiproliferative activity in the resistant double mutant H1975 cells with an IC50 of 0.19 μM. It also exhibits antitumor activity in a murine H1975 xenograft model.</p>Fórmula:C28H30Cl2F2N6O4Cor e Forma:SolidPeso molecular:623.48Tesevatinib tosylate
CAS:<p>Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.</p>Fórmula:C31H33Cl2FN4O5SCor e Forma:SolidPeso molecular:663.59Vps34-IN-3
<p>Vps34-IN-3 is a potent, selective, and orally bioavailable inhibitor of VPS34 kinase .</p>Fórmula:C14H20N4O2Cor e Forma:SolidPeso molecular:276.33Tyrphostin 63
CAS:<p>Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.</p>Fórmula:C10H8N2OCor e Forma:SolidPeso molecular:172.183EGFR/BRAF-IN-1
<p>EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.</p>Fórmula:C26H28ClN3O4Cor e Forma:SolidPeso molecular:481.97GSK3β-IN-2
CAS:<p>GSK3β-IN-2 (Compound S01) is an inhibitor of GSK3β with an IC50 of 0.35 nM. It activates the Wnt/β-catenin signaling pathway, promoting neurogenesis and neurite outgrowth. GSK3β-IN-2 reduces tau protein phosphorylation induced by Aβ at the Ser396 site, thereby decreasing neurofibrillary tangles. Furthermore, GSK3β-IN-2 improves Alzheimer's disease symptoms in a zebrafish model.</p>Fórmula:C25H18N4OCor e Forma:SolidPeso molecular:390.437
